RBC Capital analyst Glenn Novarro raised his price target on Abbott to $77, saying that while the company is faced with “tougher comps” in Q3 relative to the 7.5% organic growth in the first half of 2018, some upside to consensus is a “distinct possibility”. The analyst is particularly positive on the Medical Devices and Diagnostics segments potentially driving the upside thanks to the momentum of new products such as Libre and Alinity. Novarro keeps his Outperform rating on Abbott and also raises his FY19 EPS view to $3.30 from $3.27.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.